Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
At lower doses, patients maintained the improvements in tissue health reported at week 12 out until week 36. Clinical remission was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated. EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis. VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.MarketBeat
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy GlobeNewswire
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
EPRX
Sec Filings
- 1/8/26 - Form 6-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- EPRX's page on the SEC website